CELL INTELLIGENCE · 肿瘤细胞治疗研究

乳腺癌中 TIL（肿瘤浸润淋巴细胞）在不同 MammaPrint®分类间存在差异

Tumour-infiltrating lymphocytes differ across MammaPrint® classifications in breast cancer.

乳腺癌围手术期外周 NK 细胞活性变化及其与临床病理特征的关联：单中心队列研究

Perioperative Changes in Peripheral Natural Killer Cell Activity and Their Association With Clinicopathological Features in Breast Cancer: A Single-Ce

手术治疗似乎对乳腺癌患者外周血 NK 细胞活性产生有利影响。NK 活性变化与临床病理参数之间缺乏明确相关性，提示 NK 反应可能反映个体化的免疫能力，而非肿瘤特异性特征。需要整合 NK 细胞亚群和功能表型分析的大型前瞻性研究，以更好地界定 NK 细胞活性在乳腺癌中的预后和预测价值。

静息肥大细胞的转录特征与 HR(+)HER2(-) 乳腺癌疾病结局改善相关

A transcriptional signature of resting mast cells is associated with improved disease outcome in HR(+)HER2(-) breast cancer.

小体积三阴性和 HER2 阳性早期乳腺癌：首选手术还是新辅助化疗？

Small Triple-Negative and HER2-Positive Early Breast Cancer: Upfront Surgery or Neoadjuvant Chemotherapy?

新辅助化疗-免疫治疗时代三阴性乳腺癌生物标志物指导管理的进展与挑战

Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy.

采用自动化感兴趣区配准对乳腺癌 TIL（肿瘤浸润淋巴细胞）评分进行纵向评估

Longitudinal evaluation of tumor-infiltrating lymphocyte scoring using automated region of interest registration in breast cancer.

我们提出了首个用于纵向 ROI 配准以支持乳腺癌中 TIL 评分的自动化框架。

AI 辅助的 TIL（肿瘤浸润淋巴细胞）图像分析作为未接受化疗的 Luminal 型乳腺癌预后标志物

AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naïve luminal breast cancer.

化疗-免疫治疗，一种用于治疗小鼠模型中 HER2 阳性乳腺癌的联合方法

Chemo-Immunotherapy, a Combination Approach for the Treatment of HER2-Positive Breast Cancer in a Mouse Model.

TIL（肿瘤浸润淋巴细胞）作为乳腺癌新辅助化疗疗效的预测因子：形态学特征描述超越定量分析的附加价值

Tumor-Infiltrating Lymphocytes as Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: Added Value of Morphological Characterization B

短期术前内分泌治疗对雌激素受体阳性、HER2 阴性乳腺癌肿瘤形态学和免疫组化特征的影响

Effects of short-course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor-positive, HER2-negat

短期术前 ET 在 ER 阳性、HER2 阴性乳腺癌中诱导快速且可重复的形态学和免疫表型变化。Ki67 定义的反应与基因组风险和 PR 表达相关，而微环境特征似乎预测价值有限。